A novel three-dimensional high-throughput screening approach allows researchers to identify inducers of a mutant KRAS selective lethal phenotype.
Browsing: emerging therapies
This world-first-treatment could potentially offer hope to lung cancer patients with previously untreatable lung tumors.
Advanced triple-negative breast cancer patients who have inherited a BRCA mutation are twice as likely to benefit from carboplatin as docetaxel, a novel study suggests.
AstraZeneca (DE, USA) and Medimmune (MD, USA), recently announced results from the ARCTIC trial in third-line non-small cell lung cancer (NSCLC).
Details of the KEYNOTE-189 study have been announced by Merck (known as MSD outside the United States and Canada).
The FDA halted a Phase I/II trial that uses AstraZeneca’s Imfinzi (durvalumab) following the death of a patient.
The world’s third most common cancer, colorectal cancer (CRC) is responsible for an estimated 694,000…
John Ellwood discusses the treatment he underwent following his diagnosis with myeloma.
Investigators have discovered why Huntington’s disease is so toxic to cancer cells and are harnessing it as a novel approach to treat cancer.
The American Society of Clinical Oncology (ASCO) has named adoptive cell immunotherapy as their clinical cancer Advance of the Year.